Takeda angry at NICE negativity on CDF drug Adcetris
Japanese pharma major Takeda Pharmaceutical (TYO: 4502) has expressed its disappointment at preliminary draft guidance from the UK's National Institute for Health and Care Excellence (NICE), which does not recommend Adcetris (brentuximab vedotin) – a drug which is on the old UK’s Cancer Drugs Fund (CDF) list.
Brentuximab vedotin is used to treat some people with Hodgkin’s lymphoma (HL). It is available in the old CDF – the fund set up to pay for cancer drugs that were not available on the National Health Service (NHS) – for two out of the three indications looked at by the NICE, the medicines cost-effectiveness watchdog for England and Wales.
The NICE had not previously appraised brentuximab vedotin, which can cost between £69,000 ($89,750) and £87,000 per patient per course for any of these indications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze